Company: QTIWW
Filing Date: 2025-12-31
Form Type: 424B3
Source: 0001628280-25-059235
Chunk: 170

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-12-31
Form: 424B3
Chunk 170
---
 Scanners in large scale production.

#### Our Competitive Strengths
We believe that our competitive strengths include the following:

• The world-wide market for medical imaging is large and it has a potential to expand in the areas where the Company has differentiation;

• a non-ionizing, non-contrast dye injection imaging modality;

• an imaging modality with superior performance as compared to traditional mammogram with respect to specificity (false positive), thus less unnecessary emotional trauma for patients, reduced numbers of invasive follow-up procedures and a reduction of costs for both patient and broader society;

• an imaging modality with the potential to offer superior specificity compared to screening breast MRI for younger women (under 40 years of age) at above-average risk. By reducing false positives, it holds the potential of sparing patients from undue emotional distress, limiting unnecessary biopsies and follow-up procedures, and ultimately decreasing healthcare costs for both individuals and society;

• a lower price point than conventional high-energy imaging equipment;

• the Company’s technology can be deployed to LREs because of its automation, small footprint, no shielding, no contrast-dye injection;

• the Company’s technology is portable and can be used in POC settings such as LREs;

• the Company’s technology is deployable in outdoor settings such as sports, military, and naval settings;

<div align='center'>103</div>

• the Company’s technology reduces the barriers to testing and follow up-care for women, as there is no need for specialized training and the technology is well-suited for lowering health care costs by being affordable and easily accessed;

• the Company’s technology provides optimized patient experience, as no radiation is involved, with the patient being able to be followed with no limitation to imaging frequency;

• the Company’s technology is well-suited for traditional tertiary care hospitals and additionally for DTC and DTP applications, that are outside these institutions;

• the Company’s technology is uniquely proprietary, disruptive and a one-of-a kind product that can address a variety of unmet medical needs in the medical marketplace;

• the Company’s scanner features a uniquely simple design with a small number of components, which in turn significantly reduces the cost of the BOM, COGS, and the total-cost-of-ownership, and enables a lower ASP compared to other available systems, thus making it much more affordable to large mass deployments; and

• the Company’s products have potential strong revenue growth, with capital purchase supporting substantial long-term gross margin.

#### Our Strategies
We believe that our strategies include the following:

•